A recent report by the National Alliance of Healthcare Purchaser Coalitions found that the lack of employer-relevant elements in value assessments could lead to gaps in addressing employer and plan sponsor needs.
The report, “Employer Rx Value: A framework developed by the National Alliance Medical Director Advisory Council,” outlines a number of key recommendations for employers and future research.
“An important consideration emerging from the review of value assessment models is that collection of employer-relevant data should be incorporated more systematically into pivotal clinical trials of promising therapies,” the report states. “Additionally, similar data should also be integrated into post-marketing studies of new drugs to expand stakeholder understanding of value relevant to employers.”
To read the report in PDF format, click here.
